VIVUS (VVUS) Gets Jump on Arena (ARNA); Quietly Discloses Qsymia Availability in U.S.
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
Earlier in the session, VIVUS, Inc. (Nasdaq: VVUS) filed an 8-K with the U.S. SEC disclosing that its weight-loss drug Qsymia was available in the U.S. market. The announcement was made on Qsymia.com.
Investors appeared to be apprehensive on the news early Monday, with VIVUS just now making a run into positive territory. Curiously, peer Arena Pharma (Nasdaq: ARNA) is also higher Monday, despite its weight-loss drug, Belviq, not expected to be available until early in 2013.
Arena is up 1.3 percent while VIVUS is 0.9 percent better.
Investors appeared to be apprehensive on the news early Monday, with VIVUS just now making a run into positive territory. Curiously, peer Arena Pharma (Nasdaq: ARNA) is also higher Monday, despite its weight-loss drug, Belviq, not expected to be available until early in 2013.
Arena is up 1.3 percent while VIVUS is 0.9 percent better.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants fast track status to Rein Therapeutics drug for lung fibrosis
- Powerus wins $22.3M contract for counter-drone work in Middle East
- Aveanna Healthcare prices secondary offering at $11.75 per share
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
